Literature DB >> 29073801

Management of gastrointestinal complications in hereditary transthyretin amyloidosis: a single-center experience over 40 years.

Jonas Wixner1, Ole B Suhr1, Intissar Anan1.   

Abstract

INTRODUCTION: Hereditary transthyretin amyloidosis (ATTRm amyloidosis) is a rare disease caused by the deposition and accumulation of insoluble non-native transthyretin fibrils in the body. The disease inevitably results in widespread organ disruption, and poor life expectancy. The GI tract is one organ system vulnerable to disruption and, although the clinical presentation of the disease varies, GI involvement affects most patients with ATTRm amyloidosis. Areas covered: This article presents our experience with diagnosing and treating the GI symptoms of ATTRm amyloidosis patients at our center over the last 40 years, in the Swedish clustering area of the disease. Our aim is to help other physicians to better manage GI complications in patients with this rare but widespread condition. Expert commentary: GI symptoms are debilitating complications for ATTRm amyloidosis patients to experience, yet with the appropriate questioning and diagnosis methods, symptomatic treatments of these symptoms can be implemented to provide relief. Further, patients with fewer GI complications and a good nutritional status are also better candidates for liver transplantation which, in selected cases, is the best disease-modifying treatment of ATTRm amyloidosis to date.

Entities:  

Keywords:  Amyloidosis; familial amyloid neuropathy; gastric emptying; gastrointestinal tract; liver; therapeutics; transthyretin

Mesh:

Substances:

Year:  2017        PMID: 29073801     DOI: 10.1080/17474124.2018.1397511

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  6 in total

Review 1.  Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.

Authors:  Isabel Conceição
Journal:  Clin Auton Res       Date:  2019-08-09       Impact factor: 4.435

Review 2.  Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis.

Authors:  Laura Obici; Ole B Suhr
Journal:  Clin Auton Res       Date:  2019-08-26       Impact factor: 4.435

3.  Abdominal fat pad biopsies exhibit good diagnostic accuracy in patients with suspected transthyretin amyloidosis.

Authors:  Hedvig Paulsson Rokke; Nima Sadat Gousheh; Per Westermark; Ole B Suhr; Intissar Anan; Elisabet Ihse; Björn Pilebro; Jonas Wixner
Journal:  Orphanet J Rare Dis       Date:  2020-10-08       Impact factor: 4.123

Review 4.  Multidisciplinary supportive care in systemic light chain amyloidosis.

Authors:  Bou Zerdan Maroun; Sabine Allam; Chakra P Chaulagain
Journal:  Blood Res       Date:  2022-05-20

Review 5.  Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy.

Authors:  Thierry Gendre; Violaine Planté-Bordeneuve
Journal:  Clin Auton Res       Date:  2019-09-10       Impact factor: 4.435

6.  Fecal calprotectin levels are elevated in transthyretin amyloidosis patients with gastrointestinal manifestations.

Authors:  Radislav Nakov; Stayko Sarafov; Ventsislav Nakov; Mariana Gospodinova; Gianluca Ianiro; Tihomir Todorov; Albena Todorova; Ivailo Tournev
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.